Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma.
Sumanta Kumar Pal(City Of Hope National Medical Center), Laurence Albigès(Institut Gustave Roussy), Mike Roy(Novartis (United States)), Shunji Takahashi(Japanese Foundation For Cancer Research), Ritesh R. Kotecha(Memorial Sloan Kettering Cancer Center), Nicole Kundamal(Novartis (United States)), Joel Picus(Washington University in St. Louis), Patrizia Barzaghi-Rinaudo(Novartis (Switzerland)), Alvin Wong(National University Cancer Institute, Singapore), Sherif Sharaby(Novartis (United States)), Nizar M. Tannir(The University of Texas MD Anderson Cancer Center), Peter Grell(Masaryk Memorial Cancer Institute), Cristina Suárez(Complejo Hospitalario de Salamanca), Xin Yang(Novartis (United States)), Xin Gao(Massachusetts General Hospital), Javier A Otero(Novartis (United States)), Filippo de Braud(University of Milan)
Cited by 9
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
|Journal of Clinical Oncology|2018|1.1k
Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study
|Journal of Clinical Oncology|1999|893